# Arsenous Acid for Refractory Triple-Negative Breast Cancer

Source: https://onco.cc/trials/nct06678048/  
OnCo record `nct06678048` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in triple-negative breast cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Arsenous Acid for Refractory Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT06678048 by Sun Yat-sen University, with a registry enrolment figure of 12 participants, started 2024-10-23 and due to reach its primary completion in 2026-04-22. Interventions recorded: Arsenous Acid plus Chemotherapy. Conditions listed: Breast Cancer. Triple-negative eligibility wording from the registry: "For TNBC patients with a programmed death-ligand 1 (PD-L1/22C3) positive result (combined positive score, CPS ) ≥10, eligibility requires prior treatment with chemotherapy combined with PD-1". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06678048
- Phase: 2
- Setting: A Single-Arm, Two Stage, Phase II Study of Arsenous Acid Combined With Palliative Chemotherapy for Refractory Triple-Negative Breast Cancer
- Sponsor: Sun Yat-sen University
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT06678048: https://clinicaltrials.gov/study/NCT06678048

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06678048.json